California Neuroscience Research

Sherman Oaks, California 91403

3 studies enrolling now · 17 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Anhedonia, Autism Spectrum Disorder, Depressive Disorder, Major, Episodic Migraine, Irritability Associated With Autism Spectrum Disorder, Major Depressive Disorder, Post-Traumatic Stress Disorder

Studies at this site

• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Recruiting now
• Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients — Recruiting now
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — Recruiting now
• International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder — Recruiting now
• A Study to Test Different Doses of BI 1569912 in People With Depression — Completed
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Stopped early
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
• A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression — Completed
• A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder — Completed
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo — Completed
• BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease. — Completed